{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:47:19Z","timestamp":1757314039108,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study evaluates whether race, socioeconomic status, insurance type, oncological provider type, and prior cancer treatment are associated with the suggestion and acceptance of hormonal therapy in patients with estrogen receptor (ER)-positive Ductal carcinoma in situ (DCIS). This study also assesses whether disparities exist pertaining to prescription of such medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center retrospective study included 111 patients diagnosed with DCIS between 2020 and 2021. Data collected included race, type of insurance, prescribing providers, and socioeconomic status. We used zip codes to identify the poverty levels in these areas as published in the United States Census Bureau and stratified the patients into quartiles accordingly. Chi-Square statistics were used to calculate significance levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no significant correlation between the intake of hormonal therapy and race (<jats:italic>p<\/jats:italic>\u2009=\u20090.60), insurance (<jats:italic>p<\/jats:italic>\u2009=\u20090.50), socioeconomic (<jats:italic>p<\/jats:italic>\u2009=\u20090.58), or providers (<jats:italic>p<\/jats:italic>\u2009=\u20090.99). 79.3% of women were offered endocrine therapy. Of those who were offered endocrine therapy, 70.8% accepted. Of patients not on hormonal therapy, 45.8% were not recommended the medications by their provider, and 54.2% declined treatment when offered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, patients\u2019 demographics and providers were not associated with adjuvant hormonal therapy initiation in DCIS. Our results show that abstaining from endocrine therapy in DCIS patients is both due to lack of provider recommendation and patient rejection of these medications. The wide variation in hormonal therapy treatment among ER-positive DCIS patients suggests a need for improved provider-patient communication regarding the risks and benefits of endocrine therapy in order to ensure a shared decision-making process.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06735-9","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T07:04:41Z","timestamp":1662707081000},"page":"207-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience"],"prefix":"10.1007","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1591-7239","authenticated-orcid":false,"given":"Julia","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-1914","authenticated-orcid":false,"given":"Fady","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"6735_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jncimonographs\/lgq035","volume":"41","author":"DC Allred","year":"2010","unstructured":"Allred DC (2010) (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 41:134\u2013138. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq035","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"6735_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"6735_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","volume":"19","author":"WJ Gradishar","year":"2021","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2021) NCCN Guidelines(R) insights: breast cancer, version 4.2021. J Natl Compr Canc Netw 19(5):484\u2013493. https:\/\/doi.org\/10.6004\/jnccn.2021.0023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9169","key":"6735_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993\u20132000. https:\/\/doi.org\/10.1016\/S0140-6736(99)05036-9","journal-title":"Lancet"},{"issue":"1","key":"6735_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol 12(1):21\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(10)70266-7","journal-title":"Lancet Oncol"},{"issue":"10021","key":"6735_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","volume":"387","author":"JF Forbes","year":"2016","unstructured":"Forbes JF, Sestak I, Howell A et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387(10021):866\u2013873. https:\/\/doi.org\/10.1016\/S0140-6736(15)01129-0","journal-title":"Lancet"},{"issue":"12","key":"6735_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135\u20131141. https:\/\/doi.org\/10.1016\/S1470-2045(10)70257-6","journal-title":"Lancet Oncol"},{"issue":"10021","key":"6735_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","volume":"387","author":"RG Margolese","year":"2016","unstructured":"Margolese RG, Cecchini RS, Julian TB et al (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):849\u2013856. https:\/\/doi.org\/10.1016\/S0140-6736(15)01168-X","journal-title":"Lancet"},{"key":"6735_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","volume":"68","author":"AV Barrio","year":"2017","unstructured":"Barrio AV, Van Zee KJ (2017) Controversies in the treatment of ductal carcinoma in situ. Annu Rev Med 68:197\u2013211. https:\/\/doi.org\/10.1146\/annurev-med-050715-104920","journal-title":"Annu Rev Med"},{"issue":"22","key":"6735_CR10","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1200\/JCO.2006.10.2699","volume":"25","author":"TW Yen","year":"2007","unstructured":"Yen TW, Kuerer HM, Ottesen RA et al (2007) Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol 25(22):3251\u20133258. https:\/\/doi.org\/10.1200\/JCO.2006.10.2699","journal-title":"J Clin Oncol"},{"issue":"2","key":"6735_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1634\/theoncologist.2015-0310","volume":"21","author":"HB Nichols","year":"2016","unstructured":"Nichols HB, Bowles EJ, Islam J et al (2016) Tamoxifen initiation after ductal carcinoma in situ. Oncologist 21(2):134\u2013140. https:\/\/doi.org\/10.1634\/theoncologist.2015-0310","journal-title":"Oncologist"},{"issue":"10","key":"6735_CR12","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1245\/s10434-017-5930-3","volume":"24","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC (2017) Factors influencing use of hormone therapy for ductal carcinoma in situ: a National Cancer Database Study. Ann Surg Oncol 24(10):2989\u20132998. https:\/\/doi.org\/10.1245\/s10434-017-5930-3","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6735_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cncr.20085","volume":"100","author":"TW Yen","year":"2004","unstructured":"Yen TW, Hunt KK, Mirza NQ et al (2004) Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100(5):942\u2013949. https:\/\/doi.org\/10.1002\/cncr.20085","journal-title":"Cancer"},{"key":"6735_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40064-014-0776-7","volume":"4","author":"HS Feigelson","year":"2015","unstructured":"Feigelson HS, Carroll NM, Weinmann S et al (2015) Treatment patterns for ductal carcinoma in situ from 2000\u20132010 across six integrated health plans. Springerplus 4:24. https:\/\/doi.org\/10.1186\/s40064-014-0776-7","journal-title":"Springerplus"},{"issue":"10","key":"6735_CR15","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1245\/s10434-015-4668-z","volume":"22","author":"MR Flanagan","year":"2015","unstructured":"Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH (2015) Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 to 2012 in the national cancer data base. Ann Surg Oncol 22(10):3264\u20133272. https:\/\/doi.org\/10.1245\/s10434-015-4668-z","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"6735_CR16","first-page":"351","volume":"16","author":"R Haque","year":"2010","unstructured":"Haque R, Achacoso NS, Fletcher SW et al (2010) Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 16(5):351\u2013360","journal-title":"Am J Manag Care"},{"issue":"2","key":"6735_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.amjsurg.2007.10.001","volume":"195","author":"LC Jackson","year":"2008","unstructured":"Jackson LC, Camacho F, Levine EA, Anderson RT, Stewart JH (2008) Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. Am J Surg 195(2):164\u2013169. https:\/\/doi.org\/10.1016\/j.amjsurg.2007.10.001","journal-title":"Am J Surg"},{"issue":"2","key":"6735_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-011-1762-1","volume":"131","author":"JC Livaudais","year":"2012","unstructured":"Livaudais JC, Hershman DL, Habel L et al (2012) Racial\/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 131(2):607\u2013617. https:\/\/doi.org\/10.1007\/s10549-011-1762-1","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"6735_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cncr.30425","volume":"123","author":"H Zhao","year":"2017","unstructured":"Zhao H, Hei N, Wu Y et al (2017) Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer 123(6):940\u2013947. https:\/\/doi.org\/10.1002\/cncr.30425","journal-title":"Cancer"},{"issue":"12","key":"6735_CR20","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ\u2014the LORD study. Eur J Cancer 51(12):1497\u20131510. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008","journal-title":"Eur J Cancer"},{"issue":"16","key":"6735_CR21","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L et al (2015) Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51(16):2296\u20132303. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.017","journal-title":"Eur J Cancer"},{"issue":"3","key":"6735_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T et al (2019) The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9(3):e026797. https:\/\/doi.org\/10.1136\/bmjopen-2018-026797","journal-title":"BMJ Open"},{"key":"6735_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163962","author":"D Byng","year":"2021","unstructured":"Byng D, Retel VP, Engelhardt EG et al (2021) Preferences of treatment strategies among women with low-risk DCIS and oncologists. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13163962","journal-title":"Cancers (Basel)"},{"key":"6735_CR24","volume-title":"Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer Data Points # 14","author":"BA Virnig","year":"2011","unstructured":"Virnig BA, Torchia MT, Jarosek SL, Durham S, Tuttle TM (2011) Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer Data Points # 14. Data Points Publication Series, Rockville"},{"issue":"2","key":"6735_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0378-5122(92)90003-m","volume":"14","author":"SM McKinlay","year":"1992","unstructured":"McKinlay SM, Brambilla DJ, Posner JG (1992) The normal menopause transition. Maturitas 14(2):103\u2013115. https:\/\/doi.org\/10.1016\/0378-5122(92)90003-m","journal-title":"Maturitas"},{"key":"6735_CR26","unstructured":"Center OM (2015) Community Health Needs Assessment. https:\/\/ochsner-craft.s3.amazonaws.com\/www\/static\/2015_CHNA_Ochsner_Medical_Center_final.pdf. Accessed 28 Jul 2022"},{"issue":"3","key":"6735_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-016-4030-6","volume":"160","author":"CC Madubata","year":"2016","unstructured":"Madubata CC, Liu Y, Goodman MS et al (2016) Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race. Breast Cancer Res Treat 160(3):563\u2013572. https:\/\/doi.org\/10.1007\/s10549-016-4030-6","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6735_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1634\/theoncologist.2016-0397","volume":"22","author":"C Anderson","year":"2017","unstructured":"Anderson C, Meyer AM, Wheeler SB, Zhou L, Reeder-Hayes KE, Nichols HB (2017) Endocrine therapy initiation and medical oncologist utilization among women diagnosed with ductal carcinoma in situ. Oncologist 22(5):535\u2013541. https:\/\/doi.org\/10.1634\/theoncologist.2016-0397","journal-title":"Oncologist"},{"issue":"3","key":"6735_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3816\/CBC.2008.n.032","volume":"8","author":"A Partridge","year":"2008","unstructured":"Partridge A, Winer JP, Golshan M et al (2008) Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer 8(3):275\u2013280. https:\/\/doi.org\/10.3816\/CBC.2008.n.032","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"6735_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2009.01.004","volume":"18","author":"F Kennedy","year":"2009","unstructured":"Kennedy F, Harcourt D, Rumsey N (2009) Perceptions of ductal carcinoma in situ (DCIS) among UK health professionals. Breast 18(2):89\u201393. https:\/\/doi.org\/10.1016\/j.breast.2009.01.004","journal-title":"Breast"},{"issue":"24","key":"6735_CR31","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1200\/JCO.2004.05.192","volume":"22","author":"SL Bober","year":"2004","unstructured":"Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951\u20134957. https:\/\/doi.org\/10.1200\/JCO.2004.05.192","journal-title":"J Clin Oncol"},{"issue":"1","key":"6735_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pec.2010.07.002","volume":"84","author":"S De Morgan","year":"2011","unstructured":"De Morgan S, Redman S, D\u2019Este C, Rogers K (2011) Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns 84(1):62\u201368. https:\/\/doi.org\/10.1016\/j.pec.2010.07.002","journal-title":"Patient Educ Couns"},{"issue":"3","key":"6735_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10552-010-9710-7","volume":"22","author":"N Krieger","year":"2011","unstructured":"Krieger N, Chen JT, Waterman PD (2011) Temporal trends in the black\/white breast cancer case ratio for estrogen receptor status: disparities are historically contingent, not innate. Cancer Causes Control 22(3):511\u2013514. https:\/\/doi.org\/10.1007\/s10552-010-9710-7","journal-title":"Cancer Causes Control"},{"issue":"2","key":"6735_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/jwh.2010.1986","volume":"20","author":"CP Kaplan","year":"2011","unstructured":"Kaplan CP, Napoles AM, Hwang ES et al (2011) Selection of treatment among Latina and non-Latina white women with ductal carcinoma in situ. J Womens Health (Larchmt) 20(2):215\u2013223. https:\/\/doi.org\/10.1089\/jwh.2010.1986","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"6735_CR35","first-page":"376","volume":"23","author":"DJ Oates","year":"2009","unstructured":"Oates DJ, Silliman RA (2009) Health literacy: improving patient understanding. Oncology (Williston Park) 23(4):376\u2013379","journal-title":"Oncology (Williston Park)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06735-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06735-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:36:58Z","timestamp":1665405418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06735-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6735"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06735-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was determined exempt from informed consent by the Institutional Review Boards (IRB) of the Ochsner Clinic Foundation as a retrospective chart review that involved no diagnostic or therapeutic intervention and no direct patient contact.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}